(2026). Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: A retrospective analysis. PeerJ.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Clinical Outcomes with First-line Tislelizumab Plus Lenvatinib in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis."
PeerJ 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Clinical Outcomes with First-line Tislelizumab Plus Lenvatinib in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis."
PeerJ, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.